Last reviewed · How we verify
Tritanrix-HepB/Meningitec conjugate vaccine — Competitive Intelligence Brief
phase 3
Conjugate vaccine
Immunology
Biologic
Live · refreshed every 30 min
Target snapshot
Tritanrix-HepB/Meningitec conjugate vaccine (Tritanrix-HepB/Meningitec conjugate vaccine) — GlaxoSmithKline. Tritanrix-HepB/Meningitec conjugate vaccine works by stimulating the body's immune system to produce antibodies against diphtheria, tetanus, pertussis, hepatitis B, and meningococcal serogroups A, C, W, and Y.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Tritanrix-HepB/Meningitec conjugate vaccine TARGET | Tritanrix-HepB/Meningitec conjugate vaccine | GlaxoSmithKline | phase 3 | Conjugate vaccine | ||
| Prevnar 20 | pneumococcal 20-valent conjugate vaccine (PCV20) | Pfizer Inc. | marketed | Pneumococcal conjugate vaccine | Streptococcus pneumoniae capsular polysaccharides (20 serotypes) | 2021-06-08 |
| Meningitec® | Meningitec® | GlaxoSmithKline | marketed | Conjugate vaccine | Neisseria meningitidis serogroup C polysaccharide capsule | |
| Prevenar and Meningitec | Prevenar and Meningitec | Wyeth is now a wholly owned subsidiary of Pfizer | marketed | Conjugate vaccine | Streptococcus pneumoniae polysaccharide capsule (Prevenar); Neisseria meningitidis serogroup C polysaccharide capsule (Meningitec) | |
| MCV4 | MCV4 | CanSino Biologics Inc. | marketed | Meningococcal conjugate vaccine | Neisseria meningitidis serogroups A, C, W, Y polysaccharide capsules | |
| MenACWY-DT | MenACWY-DT | Canadian Immunization Research Network | marketed | Conjugate vaccine | Neisseria meningitidis capsular polysaccharides (serogroups A, C, W, Y) | |
| MenACWY | MenACWY | LimmaTech Biologics AG | marketed | Conjugate vaccine | Neisseria meningitidis serogroups A, C, W, Y polysaccharide capsules |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Prevnar 20 · US 8,895,024 · Composition of matter · US
- — Prevnar 20 · US 10,279,033 · Method of use · US
Sponsor landscape (Conjugate vaccine class)
- GlaxoSmithKline · 26 drugs in this class
- Sanofi Pasteur, a Sanofi Company · 6 drugs in this class
- CanSino Biologics Inc. · 3 drugs in this class
- MCM Vaccines B.V. · 3 drugs in this class
- Beijing Minhai Biotechnology Co., Ltd · 3 drugs in this class
- Wyeth is now a wholly owned subsidiary of Pfizer · 2 drugs in this class
- PT Bio Farma · 2 drugs in this class
- LG Life Sciences · 2 drugs in this class
- Walvax Biotechnology Co., Ltd. · 2 drugs in this class
- Heinrich-Heine University, Duesseldorf · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Tritanrix-HepB/Meningitec conjugate vaccine CI watch — RSS
- Tritanrix-HepB/Meningitec conjugate vaccine CI watch — Atom
- Tritanrix-HepB/Meningitec conjugate vaccine CI watch — JSON
- Tritanrix-HepB/Meningitec conjugate vaccine alone — RSS
- Whole Conjugate vaccine class — RSS
Cite this brief
Drug Landscape (2026). Tritanrix-HepB/Meningitec conjugate vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/tritanrix-hepb-meningitec-conjugate-vaccine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab